BioSpace News Archive

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 US HAEA National Summit taking place in Orlando, Florida from July 20-23.

Alphyn Biologics released interim results today from the second cohort of its Phase 2a clinical trial program of AB-101a, a novel topical candidate for atopic dermatitis (AD).

CurvaFix, Inc ., a developer of medical devices to repair fractures in curved bones, today announced the close of a $39 million equity financing led by MVM Partners with participation from Sectoral Asset Management and other existing investors.

enVVeno Medical Corporation today reminded investors that it will host a virtual KOL event on Tuesday, July 18, 2023, at 3:00 PM ET.

ZoomMed Inc. (“ ZoomMed ” or the “ Corporation ”) (NEX: ZMD) is pleased to announce the full revocation as of today of the cease trade order which was issued by the Autorité des marchés financiers and the Ontario Securities Commission on October 5, 2018 pursuant to which all trading in the securities of the Corporation, whether direct or indirect, had to cease until the order is revoked (the “ CTO ”).

Galmed Pharmaceuticals Ltd. announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the “Offering”).

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting.

POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650).

Seres Therapeutics, Inc. today announced that on July 13, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 66,066 shares of its common stock to seven new employees.

Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.